App-Quantinova.ai

Fosaprepitant as a risk factor for ifosfamide induced encephalopathy: A single institution experience.

Ridhi Gupta - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Fosaprepitant

The increase in FDA-approved novel cancer drugs over the last 5 years: What factors are involved?

Idoroenyi Usua Amanam - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A new concept to target the proteasome: disrupting protein-protein interactions in the proteasome super-assembly as a way to stop the growth of cancer cells.

Maria E Gaczynska - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Bortezomib

Relationship of ionizing radiation-induced synthetic lethality of PARP inhibition in BRCA1-proficient cancer cells with p53.

Steven T. Sizemore - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Labeling recommendations based on exposure-response relationships to minimize musculoskeletal related adverse reactions of a Hedgehog inhibitor.

Stacy Shifflett Shord - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A phase II randomized study of docetaxel +/- low-dose, short course sunitinib in advanced solid tumours.

Yvonne Li'en Ang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

Population pharmacokinetics (pop PK) and exposure-safety analysis to reveal patient factors that affect AMG 900 tolerability.

Vincent F-S. Chow - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

AMG-900

Analysis of the HLA-I genotypes in patients with solid tumours who were treated with anti-HER therapy.

Javier Lopez-Gonzalez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Trastuzumab

Pre-screening test for clinical trials of Autologous T lymphocyte therapy for advanced cancer.

Michael D. Leek - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Use of immunotherapy with patient-specific antigens to select tumor specific T cell receptor (TCR) in cancer patients.

Yanyan Han - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Use of multiple antigens stimulating cellular therapy to treat patients with hepatocellular carcinoma.

Yanyan Han - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Adoptive cellular immunotherapy with APN401, autologous Cbl-b-silenced peripheral blood mononuclear cells, in patients with solid tumors.

Marc Oliver Salzberg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

APN-401

Locoregional treatment of 'immune escape' metastatic melanoma in the setting of immune checkpoint inhibition for widespread disease.

Maria Frances Coakley - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

The use of rituximab to manage B cell-mediated autoimmune thrombocytopenia (AITP) during concurrent program death ligand-1 (PD-L1) immunotherapy.

Michael Castro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

Nivolumab

Clinical experience with pembrolizumab in metastatic heavily pre-treated patients with solid cancers in a single center.

Raya Leibowitz-Amit - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

Evaluation of baseline asymptomatic dysimmunity prevalence in cancer patients receiving monoclonal anti-PD1 antibodies.

Jennifer ARRONDEAU - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Activation of tumor infiltrating lymphocytes from colorectal cancer and colorectal liver metastasis patients by anti-human PD-1 Antibody BGB-A317 in a 3D spheroid system.

Xiaoran Wu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Tislelizumab

Immune checkpoint inhibitors (ICI): A meta-analysis of immune-related adverse events (irAE) from cancer clinical trials.

Badi Edmond El Osta - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Hyperthermic pleural lavage for pleural metastasis.

Patricia L. Thompson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cisplatin

Immune effects by selective heating of membrane rafts of cancer-cells.

Magdolna Dank - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Fluvastatin

Filters

41730 Abstracts